As for lung cancer, the BTK inhibitor ibrutinib effectively suppresses the proliferation of certain EGFR mutant lung cancer cells through the inhibition of the autophosphorylation of EGFR [18]. The gene discussed is EGFR; the disease is lung carcinoma.